Literature DB >> 17390068

Functional analysis of the gene expression profiles of colorectal cancer cell lines in relation to oxaliplatin and cisplatin cytotoxicity.

Delphine Meynard1, Valérie Le Morvan, Jacques Bonnet, Jacques Robert.   

Abstract

The objective was to relate the gene expression profiles of colorectal cancer cells in culture to the in vitro cytotoxicity of cisplatin and oxaliplatin. We studied the gene expression profiles of six human colorectal cancer cell lines, using the Atlas Plastic Human 8K Microarray from Clontech, and related it to the in vitro cytotoxicities of oxaliplatin and cisplatin obtained by inhibition of exponential growth of cells. We calculated the Pearson's coefficients of correlation (r) between gene expression and drug IC50. A functional analysis was performed using the Gene Ontology Consortium database. Results were validated on a series of representative genes by real-time quantitative PCR. Validation of the significance of the coefficients of correlation was also performed using a leave-one-out analysis. We identified 394 genes whose expression was significantly correlated (P<0.05) to oxaliplatin cytotoxicity and 40 with cisplatin cytotoxicity. Three major functions were preferentially involved in oxaliplatin activity: protein synthesis, cell energetics and response to oxidative stress. No significant correlation was observed between oxaliplatin or cisplatin cytotoxicity and the expression of genes involved in DNA repair, cell proliferation or cell adhesion. A strongly significant correlation was found between the microarray and the rt-PCR approaches (r=0.968, P<10(-6)). The leave-one-out analysis showed that the same functions still appeared significantly involved in the activity of both drugs. Based on the functional analysis, we hypothesized that oxaliplatin would specifically form protein adducts during synthesis, thus exposing their thiol groups, which are known to be especially vulnerable to reactive oxygen species.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17390068

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

1.  Genome-wide single-nucleotide resolution of oxaliplatin-DNA adduct repair in drug-sensitive and -resistant colorectal cancer cell lines.

Authors:  Courtney M Vaughn; Christopher P Selby; Yanyan Yang; David S Hsu; Aziz Sancar
Journal:  J Biol Chem       Date:  2020-04-16       Impact factor: 5.157

2.  Embryonic stem cells lacking the epigenetic regulator Cfp1 are hypersensitive to DNA-damaging agents and exhibit decreased Ape1/Ref-1 protein expression and endonuclease activity.

Authors:  Courtney M Tate; Melissa L Fishel; Julianne L Holleran; Merrill J Egorin; David G Skalnik
Journal:  DNA Repair (Amst)       Date:  2009-10-15

Review 3.  DNA repair proteins as molecular targets for cancer therapeutics.

Authors:  Mark R Kelley; Melissa L Fishel
Journal:  Anticancer Agents Med Chem       Date:  2008-05       Impact factor: 2.505

4.  Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors.

Authors:  Juliette Descoeur; Vanessa Pereira; Anne Pizzoccaro; Amaury Francois; Bing Ling; Violette Maffre; Brigitte Couette; Jérôme Busserolles; Christine Courteix; Jacques Noel; Michel Lazdunski; Alain Eschalier; Nicolas Authier; Emmanuel Bourinet
Journal:  EMBO Mol Med       Date:  2011-03-24       Impact factor: 12.137

5.  Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells.

Authors:  Kawin Leelawat; Siriluck Narong; Wandee Udomchaiprasertkul; Surang Leelawat; Sumalee Tungpradubkul
Journal:  Cancer Cell Int       Date:  2009-01-08       Impact factor: 5.722

6.  Double siRNA-targeting of cIAP2 and LIVIN results in synergetic sensitization of HCT-116 cells to oxaliplatin treatment.

Authors:  Andrey S Bavykin; Alexandra A Korotaeva; Stanislav V Poyarkov; Alexandr V Syrtsev; Sergei A Tjulandin; Alexandr V Karpukhin
Journal:  Onco Targets Ther       Date:  2013-09-23       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.